Lasa Supergenerics News

Lasa Supergenerics promoter discloses FY26 status

Omkar Herlekar reported no new share encumbrances in FY26. The disclosure was made under SEBI (SAST) Regulations.

LASA Supergenerics Q4FY26 related party transactions

LASA Supergenerics disclosed related party transactions for Q4FY26, including remuneration and donations totaling ₹35.36 lakh.

Lasa Supergenerics reports Q4FY26 net loss

Lasa Supergenerics reported a net loss of ₹416.44 lakh for Q4FY26. Revenue from operations stood at (₹13.15) lakh.

Lasa Supergenerics Board Meet Set for May 29, 2026

Lasa Supergenerics schedules board meeting on May 29, 2026 to approve audited financial results for Q4 and full year ended March 31, 2026.

LASA Supergenerics Declares Non-Applicability of Large Entity Framework

LASA Supergenerics Limited has declared that it falls outside the purview of the Large Corporate category as per SEBI's framework for debt securities issuance by large entities.